Pharmacovigilance: towards a better understanding of the benefit to risk ratio.
作者信息
Simon L S
机构信息
Division of Analgesic, Anti-inflammatory and Ophthalmologic Drug Products, Center for Drug Evaluation and Research ODEV, FDA, Rockville, MD 20850, USA.
出版信息
Ann Rheum Dis. 2002 Nov;61 Suppl 2(Suppl 2):ii88-9. doi: 10.1136/ard.61.suppl_2.ii88.
Abstract
摘要
相似文献
1
Pharmacovigilance: towards a better understanding of the benefit to risk ratio.药物警戒：力求更好地理解效益风险比
Ann Rheum Dis. 2002 Nov;61 Suppl 2(Suppl 2):ii88-9. doi: 10.1136/ard.61.suppl_2.ii88.
2
The temporal association between adverse drug reactions and antirheumatic drugs utilisation in Western Australia: a retrospective study from real-world data (1995-2015).澳大利亚西部真实世界数据中药物不良反应与抗风湿药物应用之间的时间关联：一项回顾性研究（1995-2015 年）。
Rheumatol Int. 2024 Jun;44(6):1089-1099. doi: 10.1007/s00296-024-05588-3. Epub 2024 Apr 14.
3
A real-world disproportionality analysis of FDA Adverse Event Reporting System (FAERS) events for baricitinib.巴瑞替尼的美国食品和药物管理局不良事件报告系统（FAERS）事件的真实世界药物不良反应比例分析。
Expert Opin Drug Saf. 2020 Nov;19(11):1505-1511. doi: 10.1080/14740338.2020.1799975. Epub 2020 Jul 31.
4
Launch of a checklist for reporting longitudinal observational drug studies in rheumatology: a EULAR extension of STROBE guidelines based on experience from biologics registries.发布风湿病纵向观察性药物研究报告清单：基于生物制剂登记处经验的EULAR对STROBE指南的扩展
Ann Rheum Dis. 2014 Mar;73(3):628. doi: 10.1136/annrheumdis-2013-204102. Epub 2013 Sep 20.
5
Arthritis, Rheumatism and Aging Medical Information System Post-Marketing Surveillance Program.关节炎、风湿病与衰老医学信息系统上市后监测项目
J Rheumatol. 2001 May;28(5):1174-9.
6
Serious adverse drug reactions with hydroxychloroquine: a pharmacovigilance study in Vigibase®.羟氯喹的严重药物不良反应：Vigibase®中的药物警戒研究
Eur J Clin Pharmacol. 2020 Oct;76(10):1479-1480. doi: 10.1007/s00228-020-02920-1. Epub 2020 Jun 6.
7
Pharmacovigilance in Europe: Place of the Pharmacovigilance Risk Assessment Committee (PRAC) in organisation and decisional processes.欧洲的药物警戒：药物警戒风险评估委员会（PRAC）在组织和决策过程中的地位。
Therapie. 2016 Apr;71(2):161-9. doi: 10.1016/j.therap.2016.02.008. Epub 2016 Mar 8.
8
Comment on: "Pharmacovigilance in the Middle East".
Drug Saf. 2014 Aug;37(8):651-2. doi: 10.1007/s40264-014-0192-5.
9
Bisphosphonates, osteonecrosis of the jaw, and pharmacovigilance.双膦酸盐、颌骨坏死与药物警戒
N Z Med J. 2006 Dec 1;119(1246):U2334.
10
The British Society for Rheumatology biologics register.英国风湿病学会生物制剂登记册。
Ann Rheum Dis. 2005 Nov;64 Suppl 4(Suppl 4):iv42-3. doi: 10.1136/ard.2005.042499.
引用本文的文献
1
Differences in reproductive toxicology between alopecia drugs: an analysis on adverse events among female and male cases.脱发药物在生殖毒理学方面的差异：一项关于女性和男性病例不良事件的分析。
Oncotarget. 2016 Dec 13;7(50):82074-82084. doi: 10.18632/oncotarget.12617.
2
Clinical Risk Factors for the Development of Psoriatic Arthritis Among Patients with Psoriasis: A Review of Available Evidence.银屑病患者发生银屑病关节炎的临床危险因素：现有证据综述
Curr Rheumatol Rep. 2015 Oct;17(10):64. doi: 10.1007/s11926-015-0540-1.
本文引用的文献
1
The epidemiological evaluation of drugs.
Acta Med Scand Suppl. 1984;683:23-7. doi: 10.1111/j.0954-6820.1984.tb08710.x.
2
Why do doctors not report adverse drug reactions?
Neth J Med. 1985;28(12):546-50.
3
Postmarketing studies of drug efficacy.
Arch Intern Med. 1985 Oct;145(10):1791-4.
4
Postmarketing surveillance methodologies.上市后监测方法。
Drug Intell Clin Pharm. 1988 Jan;22(1):68-78. doi: 10.1177/106002808802200117.
5
Overview of different logistical approaches to postmarketing surveillance.
J Rheumatol Suppl. 1988 Oct;17:9-13.
6
Spontaneous adverse drug reaction reporting vs event monitoring: a comparison.自发药物不良反应报告与事件监测：一项比较
J R Soc Med. 1991 Jun;84(6):341-4. doi: 10.1177/014107689108400612.
Zotero 插件